Heal Venture Lab

Heal Venture Lab is a venture builder community focused on bringing capital and outcome-driven medical innovations to Asia Pacific to improve on healthcare access and affordability. The company is creating a regional accelerator with focus on biomed product and service innovations on critical unmet epidemiology while creating a hub and spoke network for Asia with Singapore as the central hub.

Dr. Jaemin Park

Managing Partner

Dr. Stephen Phua

Managing Partner

Cristan Yang

Director

Dr. Ngim Chun-Han

Venture Partner

Norrapat Shih

Venture Partner

Engagement Model

STEP 01

Initial Assessment & Selection

Rigorous screening and evaluation of biomed ventures against unmet epidemiological needs in Asia Pacific.

STEP 02

Structured Development Plan

A milestone-driven roadmap tailored to the venture — clarifying technical, clinical, and commercial priorities.

STEP 03

Access to Enterprise & Resources

Plug into the Singapore hub-and-spoke network — mentors, labs, clinical partners, and corporate channels.

STEP 04

IP Assessment

Evaluate, strengthen, and protect intellectual property to secure defensible positions in regional markets.

STEP 05

Regulatory & Compliance Support

Navigate HSA, FDA, and APAC regulatory pathways with hands-on guidance from healthcare specialists.

STEP 06

Market Entry Assessment

Go-to-market validation across APAC spokes — pricing, distribution, reimbursement, and adoption pathways.

STEP 07

Investor Readiness

Polish the pitch, data room, and financial model — positioned for capital deployment from aligned investors.

STEP 01

Onboarding & Thesis Alignment

Map the investor's mandate to HVL's thesis — biomed focus areas, stage, geography, and ticket size.

STEP 02

Curated Deal Flow Access

Priority access to a pre-vetted pipeline of biomed ventures emerging from the HVL accelerator cohorts.

STEP 03

Due Diligence Support

In-depth dossiers on IP, regulatory status, clinical evidence, and market fit — accelerating decision-making.

STEP 04

Co-Investment & Syndication

Partner alongside HVL and syndicate partners — shared conviction, shared diligence, aligned incentives.

STEP 05

Portfolio Integration

Plug portfolio companies into HVL's hub-and-spoke — unlocking clinical, commercial, and strategic synergies.

STEP 06

Performance Monitoring

Transparent reporting on milestones, clinical outcomes, and financial KPIs across the portfolio.

STEP 07

Exit & Liquidity Pathways

Structured exits via strategic M&A, follow-on rounds, and secondary opportunities across the region.

Stakeholder Economy

01 — Investor

Wide network of investors

Access to investors as well as support with the due diligence on both sides.

02 — Customer

KOLs, Doctors and key government officials

Senior government officials, top regional hospitals as well as doctors on the ground.

03 — Manufacturers

Manufacturing strategies in ASEAN markets and outside

Manufacturing players who are doing pharma as well as medical device and diagnostics.

04 — Suppliers

Regional and Local Medical Distributors

Strong partnerships with established distributors across the region to ensure reliable market access and logistics.

The Three Pillars of the Barbel Model

The Engine

High-risk early-stage platforms and "Drug Factories."

Option Value & Convexity
10x – 30x ROI Target
Power Law Fund Returner

The Sweet Spot

Clinical value inflections (Phase 1b to Phase 2 PoC).

De-risking Inflection
3x – 7x ROI Target
Primary M&A Exit Zone

The Floor

Late-stage Medtech, Diagnostics, or Digital Health.

Capital Preservation
~2x ROI Target
DPI & Velocity Focus

Strategic Objective

"Protect the J-Curve via the Floor while capturing exponential Alpha via the Engine."

Investment Process

Deal Origination

Initial Assessment (Pre-NDA)

Singapore-based venture builder community focused on bringing capital and medical innovation to the Asia-Pacific region, with social impact goals in mind.